Galderma Group AG
Clinical Trials
296
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (273 trials with phase data)• Click on a phase to view related trials
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-11-21
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 561
- Registration Number
- NCT07186413
- Locations
- 🇨🇳
Galderma Research & Development Site #5378, Shanghai, Jing'an District, China
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
- Conditions
- Chronic Pruritus of Unknown Origin
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT07074977
- Locations
- 🇺🇸
Galderma Investigational Site (site# 8893), Birmingham, Alabama, United States
🇺🇸Galderma Investigational Site (site# 7075), San Francisco, California, United States
🇺🇸Galderma Investigational Site (site# 8521), Saint Joseph, Missouri, United States
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
- Conditions
- Skin Quality Improvement
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 171
- Registration Number
- NCT07047638
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Conditions
- Systemic Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-11-13
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 162
- Registration Number
- NCT07047690
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
- Conditions
- Prurigo Nodularis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 600
- Registration Number
- NCT06988618
- Locations
- 🇺🇸
Galderma Investigational Site # 8893, Birmingham, Alabama, United States
🇺🇸Galderma Investigational Site # 7077, Phoenix, Arizona, United States
🇺🇸Galderma Investigational Site # 7060, Phoenix, Arizona, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next